Maraba MG1

Maraba MG1 is an engineered oncolytic rhabdovirus derived from the Maraba virus, specifically modified with two mutations (L123W in the M protein and Q242R in the G protein) to enhance tumor selectivity and safety. It exploits the defective interferon (IFN) signaling pathways common in many cancer cells, allowing for selective viral replication and direct oncolysis. Beyond direct cell killing, MG1 acts as a potent immune stimulator and is frequently used as a viral vector in heterologous prime-boost vaccination strategies (e.g., following an Adenovirus prime) to induce robust T-cell responses against tumor-associated antigens like MAGE-A3. It has been investigated in clinical trials for various solid tumors, including non-small cell lung cancer and gastrointestinal cancers, both as a monotherapy and in combination with checkpoint inhibitors.

Other names

MG1-MarabaMG-1-MarabaMG 1-MarabaMaraba virus MG1